Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

8.30
-0.3400-3.94%
Pre-market: 8.310.0123+0.15%06:30 EDT
Volume:2.92M
Turnover:24.38M
Market Cap:482.55M
PE:-3.37
High:8.70
Open:8.58
Low:8.18
Close:8.64
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.84
T/O Rate:6.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:1.96
PE(LYR):-3.67

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Capricor Therapeutics (CAPR), Enovis (ENOV) and Progyny (PGNY)

TIPRANKS
·
May 09

Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Benzinga
·
May 08

H.C. Wainwright Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 08

Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002

Reuters
·
May 08

Capricor Therapeutics Inc - Alleges Ns Pharma Failed to Prepare for Deramiocel Launch and Breached Agreement - SEC Filing

THOMSON REUTERS
·
May 08

Capricor Therapeutics Inc - Files Lawsuit and Seeks Preliminary Injunction in New Jersey Court on May 7, 2026 - SEC Filing

THOMSON REUTERS
·
May 08

Earning Preview: Capricor Therapeutics this quarter’s revenue is expected to decrease by 100%, and institutional views are bullish

Earnings Agent
·
May 06

Capricor CFO Anthony Bergmann disposes of 25,000 shares worth $792,540

Reuters
·
May 05

Capricor EVP, General Counsel Karen Krasney disposes 25,000 shares for $792,548‬

Reuters
·
May 05

Capricor Therapeutics schedules first-quarter 2026 financial results conference call and webcast

Reuters
·
May 05

Press Release: Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Dow Jones
·
May 05

Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data Release - What's Changed

Simply Wall St.
·
May 03

Capricor reports Phase 3 HOPE-3 trial results for Deramiocel in Duchenne muscular dystrophy

Reuters
·
Apr 22

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

Capricor Therapeutics (CAPR) Gets a Buy from Roth MKM

TIPRANKS
·
Apr 15

Capricor director Karimah Es Sabar disposes of $0.2 million common shares

Reuters
·
Apr 04

Capricor director Karimah Es Sabar disposes of common shares worth $3.5 million

Reuters
·
Apr 02

Capricor EVP, General Counsel Karen Krasney disposes of CAPR shares worth $0.8 million

Reuters
·
Apr 02

Capricor CFO Anthony Bergmann disposes of $0.8 million in common shares

Reuters
·
Apr 02

Capricor Therapeutics announces annual shareholder meeting, issues proxy statement

Reuters
·
Apr 01